Shorter regimen non-inferior to standard care, but not ready for prime-time
ORLANDO -- Although a shorter duration of dual antiplatelet therapy (DAPT) was non-inferior to the standard regimen among acute coronary syndrome (ACS) patients getting drug-eluting stents (DES) in the SMART-DATE trial, a signal of excess MIs led investigators to caution against the interpretation that the two are equally safe.